Company Profile
Autolus Therapeutics plc Stock Price, News & Analysis
- Ticker:
- AUTL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Stock performance
2.00 USD (+5.26%)
Close
Last updated: August 6, 2026
466M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, AUTL closed up 5.26% at $2.00. No new same-company headline was identified in the current news window.
Company overview
Programmable T-Cell Therapy Company
Autolus Therapeutics develops, manufactures, and commercializes next-generation T-cell therapies for cancer and autoimmune disease using modular cell-programming technologies.
AUCATZYL
AUCATZYL, or obecabtagene autoleucel, is an autologous CD19 CAR T-cell therapy commercialized for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Fast Off-Rate CAR Design
Obe-cel uses a fast off-rate CD19 binding domain intended to reduce excessive T-cell activation while preserving antitumor activity and persistence.
Integrated Manufacturing
Autolus controls manufacturing and product delivery, supporting launches in the United States and United Kingdom and providing infrastructure for additional cell-therapy programs.
Pipeline Expansion
The company is extending its T-cell platform into additional hematologic cancers and autoimmune disease while building on physician experience with obe-cel.
Future catalysts
Autolus’s next catalyst is AUCATZYL commercial launch execution and any follow-on CAR-T update that proves the franchise can scale. The market is watching whether the cell-therapy rollout can translate into durable adoption.
Recent news
- 01
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
Source: Autolus Therapeutics plc
- 02
- 03
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Autolus Therapeutics plc
- 04
Autolus Therapeutics to Participate in Upcoming Investor Conference
Source: Autolus Therapeutics plc
- 05
Autolus Therapeutics Receives Prix Galien UK Award
Source: Autolus Therapeutics plc
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Autolus Therapeutics plc (AUTL)?
Autolus Therapeutics plc (AUTL) most recently closed at 2.00 USD, a +5.26% move versus the previous session.
What is the market cap of Autolus Therapeutics plc (AUTL)?
Autolus Therapeutics plc currently has a market capitalization of 466M USD on BioPharmSignal.
What does Autolus Therapeutics plc do?
Programmable T-Cell Therapy Company Autolus Therapeutics develops, manufactures, and commercializes next-generation T-cell therapies for cancer and autoimmune disease using modular cell-programming technologies. AUCATZYL AUCATZYL, or obecabtagene autoleucel, is an autologous CD19 CAR T-cell therapy commercialized for adults with relapsed or refractory...
On which exchange is AUTL stock listed?
Autolus Therapeutics plc (AUTL) is associated with NASDAQ, United Kingdom, Biopharma.
What is CAR-T?
Autolus’s next catalyst is AUCATZYL commercial launch execution and any follow-on CAR-T update that proves the franchise can scale.
Which conditions is Autolus Therapeutics plc targeting with CAR-T?
Autolus Therapeutics plc is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Autolus Therapeutics plc describe recent progress with CAR-T?
Autolus’s next catalyst is AUCATZYL commercial launch execution and any follow-on CAR-T update that proves the franchise can scale.
What is Programmable?
Programmable T-Cell Therapy Company Autolus Therapeutics develops, manufactures, and commercializes next-generation T-cell therapies for cancer and autoimmune disease using modular cell-programming technologies.